SHENZHEN ARIMAB BIOPHARMACEUTICALS
Shenzhen Arimab Biopharmaceuticals is engaged in the development and marketing of monoclonal antibody therapies.
SHENZHEN ARIMAB BIOPHARMACEUTICALS
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Shenzhen, Guangdong, China
Country:
China
Status:
Active
Similar Organizations
Biochem Pharmaceuticals
Biochem Pharmaceuticals engages in the discovery, development, and production of medicines.
More informations about "Shenzhen Arimab Biopharmaceuticals"
Shenzhen Arimab Biopharmaceuticals - Crunchbase
Shenzhen Arimab Biopharmaceuticals is engaged in the development and marketing of monoclonal antibody therapies. Lists Featuring This Company. Edit Lists Featuring This …See details»
Shenzhen Arimab Biopharmaceuticals - PitchBook
Shenzhen Arimab Biopharmaceuticals is headquartered in Shenzhen, China. What industry is Shenzhen Arimab Biopharmaceuticals in? Shenzhen Arimab Biopharmaceuticals’s primary …See details»
Shenzhen Arimab Biopharmaceuticals Co., Ltd: Drug pipelines, …
Jul 15, 2023 Explore Shenzhen Arimab Biopharmaceuticals Co., Ltd with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Infectious ...See details»
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Arimab Biomedical Co., Ltd (Arimad) Established in July 2018 and located at the Hepalink Group HQ that is situated at the northern part of the Shenzhen High-Tech Industrial …See details»
Aridis Pharmaceuticals | Aridis Pharmaceuticals Forms Subsidiary …
Feb 27, 2018 The jointly owned subsidiary company will be named Shenzhen Arimab Biopharmaceuticals Co., Ltd., and headquartered in China’s largest technology hub, …See details»
Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its ...
Feb 27, 2018 The jointly owned subsidiary company will be named Shenzhen Arimab Biopharmaceuticals Co., Ltd., and headquartered in China's largest technology hub, Shenzhen.See details»
Shenzhen Arimab Biopharmaceuticals Co., Ltd. - scrip.citeline.com
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183See details»
BRIEF—Aridis Pharma set up MAb joint venture in China
Feb 27, 2018 The jointly owned subsidiary company will be named Shenzhen Arimab Biopharmaceuticals, and headquartered in China's largest technology hub, Shenzhen. The …See details»
Shenzhen Arimab Biopharmaceuticals - Crunchbase
Organization. Shenzhen Arimab Biopharmaceuticals . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies …See details»
Aridis Pharmaceuticals, Inc | Insights
Apr 12, 2023 Shenzhen Arimab Biopharmaceuticals Co., Ltd. See more in Biomedtracker. Latest on Aridis Pharmaceuticals, Inc. Already A Biomedtracker Subscriber? You have access to the …See details»
Aridis’ AR-301 Monoclonal Antibody is Among the First
Jul 12, 2023 This program is licensed to the Serum Institute of India and Shenzhen Arimab. AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb directed against the F-protein of …See details»
Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd. - Drug pipelines
Explore Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Infectious Diseases, Technology …See details»
Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its ...
SAN JOSE, Calif., Feb. 27, 2018 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives …See details»
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Insights
Shenzhen Arimab Biopharmaceuticals; Shenzhen Hepalink Pharmaceutical; See more in Biomedtracker. Latest on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Already A …See details»
Li Li: Positions, Relations and Network - MarketScreener
Oct 30, 2024 Li Li is a businessperson who founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. and who has been at the head of 5 different companies. Presently, he holds the …See details»
Tosatoxumab - Drug Targets, Indications, Patents - Synapse
AR-101 (HAP). AR-101 is a fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11, which accounts for approximately …See details»
Company Details :: In Vivo
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183See details»
Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its ...
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced …See details»
Biologics CDMO Market to Grow by USD 10.63 Billion from 2024 …
2 days ago NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) …See details»
002399.SZ - | Stock Price & Latest News | Reuters
3 days ago Get Shenzhen Hepalink Pharmaceutical Group Co Ltd (002399.SZ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSee details»